Long‐term symptom control of gastro‐oesophageal reflux disease 12 years after laparoscopic Nissen or 180° anterior partial fundoplication in a randomized clinical trial. BJS 2017; 104: 852-856.
Published: 3rd February 2017
Authors: D. J. Roks, J. A. Broeders, R. J. Baigrie
Laparoscopic 180° anterior fundoplication has been shown to achieve similar reflux control to Nissen fundoplication, with fewer side‐effects, up to 5 years. However, there is a paucity of long‐term follow‐up data on this technique and antireflux surgery in general. This study reports 12‐year outcomes of a double‐blind
Patients with proven
Of the initial 163 patients randomized (Nissen 84, anterior 79), 90 (55·2 per cent) completed 12‐year follow‐up (Nissen 52, anterior 38). There were no differences in heartburn, dysphagia, gas‐related symptoms, patient satisfaction or surgical reintervention rate. Use of acid‐suppressing drugs was less common after Nissen than after 180° anterior fundoplication: four of 52 (8 per cent) and 11 of 38 (29 per cent) respectively (
The two surgical procedures provided similar control of heartburn and post‐fundoplication symptoms, with similar patient satisfaction and reoperation rates on long‐term follow‐up.Read more
You may also be interested in
Meta‐analysis of health‐related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer.
Authors: J. H. Kauppila, S. Xie, A. Johar, S. R. Markar, P. Lagergren
Notes: Only different in short term
Authors: C. Lin, H. Liu, H. Zhang, Y. Cao, R. Li, S. Wu et al.
Notes: Tumour microenvironment is important
Corrigendum: Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. BJS 2017; 104: 947-947.
Authors: J. M. Findlay, K. M. Bradley, L. M. Wang, J. M. Franklin, E. J. Teoh, F. V. Gleeson et al.
Preoperative imaging and prediction of oesophageal conduit necrosis after oesophagectomy for cancer.
Authors: P. Lainas, D. Fuks, S. Gaujoux, Z. Machroub, A. Fregeville, T. Perniceni et al.
Notes: Vascular abnormalities may be causal
Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer.
Authors: M. Bencivenga, G. Verlato, D.‐S. Han, D. Marrelli, F. Roviello, H.‐K. Yang et al.
Notes: Good performance
Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. BJS 2017; 104: 1045-1052.
Authors: H. Kim, S. W. Ahn, S. K. Hong, K. C. Yoon, H.‐S. Kim, Y. R. Choi et al.
Notes: Selected patients benefit
Authors: Z.‐X. Wang, G.‐X. Li, Z.‐W. Zhou, Z.‐P. Huang, F. Wang, R.‐H. Xu et al.
Notes: Facilitates individualized treatment
Randomized clinical trial
Randomized clinical trial of landiolol hydrochloride for the prevention of atrial fibrillation and postoperative complications after oesophagectomy for cancer. BJS 2017; 104: 1003-1009.
Authors: T. Ojima, M. Nakamori, M. Nakamura, M. Katsuda, K. Hayata, T. Kato et al.
Notes: Prevention of atrial fibrillation is beneficial
Geographic and socioeconomic factors affecting delivery of bariatric surgery across high‐ and low‐utilization healthcare systems. BJS 2017; 104: 891-897.
Authors: A. G. Doumouras, F. Saleh, A. M. Sharma, S. Anvari, S. Gmora, M. Anvari et al.
Notes: Differences between rural and urban areas
Meta‐analysis of biomarkers predicting risk of malignant progression in Barrett’s oesophagus. BJS 2017; 104: 493-502.
Authors: K. Altaf, J.‐J. Xiong, D. De la Iglesia, L. Hickey, A. Kaul
Notes: Limited clinical usefulness at present
Randomized clinical trial
Randomized clinical trial of 270° posterior versus 180° anterior partial laparoscopic fundoplication for gastro‐oesophageal reflux disease. BJS 2017; 104: 843-851.
Authors: D. J. Roks, J. H. Koetje, J. E. Oor, J. A. Broeders, V. B. Nieuwenhuijs, E. J. Hazebroek et al.
Notes: No major differences in outcomes
Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. BJS 2017; 104: 877-884.
Authors: J. S. Chang, K. H. Kim, H. I. Yoon, W. J. Hyung, S. Y. Rha, H. S. Kim et al.
Notes: Can be predicted